Medtronic (NYSE:MDT) Raised to “Buy” at Wall Street Zen

Medtronic (NYSE:MDT) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

MDT has been the topic of a number of other reports. Leerink Partners reaffirmed an “outperform” rating and issued a $119.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Mizuho raised Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Truist Financial dropped their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Price Performance

Shares of MDT stock opened at $87.20 on Friday. The stock has a 50-day moving average price of $95.80 and a 200 day moving average price of $96.48. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $111.96 billion, a price-to-earnings ratio of 24.29, a PEG ratio of 2.25 and a beta of 0.71. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic will post 5.46 EPS for the current year.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is owned by company insiders.

Institutional Trading of Medtronic

Several hedge funds have recently added to or reduced their stakes in MDT. Brighton Jones LLC lifted its holdings in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the period. Quadrant Capital Group LLC raised its holdings in Medtronic by 27.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 15,185 shares of the medical technology company’s stock worth $1,324,000 after buying an additional 3,267 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Medtronic by 1.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 162,624 shares of the medical technology company’s stock valued at $14,176,000 after buying an additional 2,313 shares in the last quarter. Finally, Level Four Advisory Services LLC lifted its stake in Medtronic by 2.6% in the second quarter. Level Four Advisory Services LLC now owns 42,526 shares of the medical technology company’s stock valued at $3,707,000 after buying an additional 1,074 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands addressable market for Stealth AXiS — The U.S. FDA cleared Medtronic’s Stealth AXiS surgical system for cranial and ENT procedures, adding to the spine clearance received in February. The broader indication increases the platform’s market opportunity for navigation + robotics in higher‑value neurosurgical/ENT cases, supporting future procedure volume and device sales. Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeries
• Positive Sentiment: Distribution deal adds a minimally invasive pain product to the portfolio — Medtronic expanded distribution with Merit Medical for the ViaVerte™ basivertebral nerve ablation (BVNA) system, a minimally invasive, implant‑free therapy for chronic low back pain. This is a commercially relevant, non‑capital product that could contribute recurring revenue and broaden Medtronic’s spine/pain offerings. Medtronic (MDT) Expands Partnership with Merit Medical for ViaVerte System
• Positive Sentiment: Analyst reaffirmation with a high price target — Needham reiterated a Buy rating and $120 price target on MDT, signaling continued analyst confidence in Medtronic’s multi‑year growth thesis (including tuck‑ins, robotics, and margin improvement). That target implies substantial upside from current levels and can support investor sentiment. Needham Reiterates Buy Rating on Medtronic
• Positive Sentiment: Strategic spin‑off plan remains a potential value catalyst — Coverage highlights Medtronic’s planned spin‑off of its high‑growth diabetes unit later this year. A diabetes spin‑off could unlock value for the parent (focused on cardiovascular, robotics, and other higher‑margin hospital businesses) and make both entities more strategically coherent. 5 Spin-Off Stocks That Could Reward Patient Investors in 2026
• Neutral Sentiment: Investor writeups argue the company is set for faster growth — Recent commentary (e.g., Seeking Alpha’s “Time For A Growth Spurt”) lays out a bullish case around robotics, procedure growth, and margin leverage; these are thematic/analytical pieces rather than direct catalysts. Impact timing is uncertain. Medtronic: Time For A Growth Spurt
• Negative Sentiment: Near‑term technicals and volume suggest selling pressure — MDT is trading below its 50‑ and 200‑day moving averages with intraday volume above average, a setup that can keep the stock under pressure despite positive fundamental news until technicals stabilize.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).